Phase II trial of preoperative radiotherapy (RT) and panitumumab (PAN) in KRAS wild type (wt) rectal cancer (RC).

@inproceedings{Mardjuadi2017PhaseIT,
  title={Phase II trial of preoperative radiotherapy (RT) and panitumumab (PAN) in KRAS wild type (wt) rectal cancer (RC).},
  author={Feby Ingriani Mardjuadi and Jean Luc Canon and J C Coche and Anne Jouret-Mourin and Christine Sempoux and J. Goeminne and Thierry Delaunoit and Javier Barrio Carrasco and Peter Vuylsteke and Yves Humblet and Nicolas Meert and Marc van den Eynde and Anne Moxhon and Jean-Pascal Machiels},
  year={2017}
}
e14060 Background: The addition of anti Epidermal Growth Factor Receptor (EGFR) monoclonal antibodies (mabs) to preoperative chemoradiation in RC has produced low pathological complete response (pCR) rate. The postulated reasons for the poor outcome are: lack of patient selection, suboptimal treatment sequencing, and potential negative interaction between anti EGFR mabs and chemotherapy (CT) when used concurrently as radiosensitizers. Given these issues, we conducted a phase II trial of PAN in… CONTINUE READING

Similar Papers

Topics from this paper.